Latest News

Cambridge, UK.  22 October 2020.  Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced  that STC-15, its first-in-class drug candidate targeting […]

Dublin, Ireland.  9 September 2020.  FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA […]

MILPITAS, California.  September 2, 2020. PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment of advanced peripheral artery disease (PAD), announced today that they received Breakthrough Device designation from the U.S. Food and […]

Galway, Ireland.  14 July 2020.  Seroba’s portfolio company, Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill the potential of the INNOVO® brand in the large and under-served US Stress […]

Hamilton, Ontario and Boston.  25 June 2020.  Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common […]

Dublin, Ireland.  25 June 2020.  Seroba’s portfolio company, PrecisionBiotics Group has been acquired by Novozymes. Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health.  Its products include the regular […]

United Kingdom.  22 June 2020.  A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective treatment option for Stress Urinary Incontinence in adult females. (Authors: Ash […]

Dublin and Clonmel, Ireland. June 4, 2020.   Shorla Pharma Limited (‘Shorla’), an Irish specialty pharmaceutical company has today announced the completion of a Series A investment of $8.3m.  The financing was led by Seroba Life Sciences […]

Alcester, Warwickshire, UK.  01 June 2020.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology innovation company, today announced that it has been proudly supporting the ongoing National Health Service (NHS) […]

Hamilton, Ontario.  23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James […]

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top